The U.S. Department of Justice has filed an appeals court brief supporting the right of Medicare officials to negotiate ...

Topline: Taxpayers spent $74.5 million to help develop the prostate cancer-fighting drug Xtandi, but its sky-high sticker ...

Swiss generic drug manufacturer Sandoz has agreed to pay $275 million to resolve claims by U.S. consumers and others who ...

A new study from the USC Schaeffer Center shows that out-of-pocket costs for brand-name medications have increased sharply ...

Providers are sympathetic to Medicare enrollees’ concerns but don’t agree on their role in helping patients find less costly ...

Expected out-of-pocket costs for commonly prescribed brand name medications have grown substantially for Medicare Part D ...

Trump could either weaken the negotiations in a way that benefits the pharmaceutical industry, or try to achieve even deeper ...

Debate over whether or not the Affordable Care Act, commonly known as Obamacare, worked and how President Trump's executive ...

While Trump's tariffs could have a broad impact on healthcare prices, it is likely they will not have the devastating result ...

That leap forward came at a sky-high price: more than $2 million per dose, making Zolgensma then the costliest one-time treatment ever. How did a drug rooted, like many, in seed money from the U.S ...

WASHINGTON, DC - OCTOBER 06: Activists protest the price of prescription drug costs in front of the ... [+] U.S. Department of Health and Human Services (HHS) building Your father’s rheumatoid ...

The Maryland House of Delegates has voted overwhelmingly to allow a state board to extend its mandate for lowering ...